Saturday, November 14, 2026

Litecoin On Bearish Momentum: 5.46% Down In The Last 6 Hours

ViaNews Editorial Team

December 21, 2020

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Litecoin On Bearish Momentum: 5.46% Down In The Last 6 Hours

Litecoin is currently on bearish momentum. At 15:06 EST on Mon 21 Dec, Litecoin is at $103.82 and down by 5.46% in the last 6 hours.

Litecoin Range

Over the last six hours, Litecoin's higher value was $109.49 and the lower value was $103.77.

Over the last twelve hours, Litecoin's higher value was $112.72 and the lower value was $103.77.

Concerning Litecoin's daily highs and lows, it's 0.048% up from its trailing 24-hour low of $103.77 and 11.957% down from its trailing 24-hour high of $117.92.

Concerning Litecoin's yearly highs and lows, it's 306.023% up from its 52-week low and 16.112% down from its 52-week high.

News about Bitcoin

How to invest in Bitcoin: the major ways to buy, their pros and cons, and the strategies to consider. According to Business Insider on Fri Dec 18, ""Bitcoin's heightened day-to-day volatility makes this especially true," says Ari Wald.", "Start small, rather than big: Given its short history and still highly unpredictable behavior, it's usually wise to keep your initial investment in Bitcoin relatively limited. "

The CIO of a new crypto fund that has returned 220% to investors this year explains why Bitcoin topped $20,000 for the first time ever this week - and shares another digital currency set to become.... According to Business Insider on Sat Dec 19, ""The core thesis supporting crypto and Bitcoin is that this is a once-in-a-generation style technological breakthrough that's penetrating multiple multi-trillion-dollar markets," he added. ", ""That's a signal from a well-established financial institution that there's more to crypto than Bitcoin," he said."

Crypto FOMO makes even a 350% premium on Bitcoin look appealing. According to Bloomberg Quint on Sat Dec 19, ""That's not to say advisors can't learn how to use crypto apps or Cash App, but if you want to get Bitcoin in existing legacy financial systems -- where almost all the money is -- you need something that works in that system."", "Companies that dabble in crypto-related industries have served as a proxy for exposure since the Bitcoin bubble of 2017. "

Elon Musk inquired on twitter about 'large' Bitcoin transactions after a crypto booster suggested he convert Tesla's balance sheet. According to Business Insider on Mon Dec 21, "Before the exchange with Saylor, he tweeted "Bitcoin is my safe word," but then followed up by saying, "Just kidding, who needs a safe word anyway!?"", "Following the Saylor conversation, Musk tweeted: "Bitcoin is almost as bs as fiat money," and then suggested to his followers he's a fan of Dogecoin, a parody cryptocurrency."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com